PE20010545A1 - Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico - Google Patents

Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico

Info

Publication number
PE20010545A1
PE20010545A1 PE2000000705A PE0007052000A PE20010545A1 PE 20010545 A1 PE20010545 A1 PE 20010545A1 PE 2000000705 A PE2000000705 A PE 2000000705A PE 0007052000 A PE0007052000 A PE 0007052000A PE 20010545 A1 PE20010545 A1 PE 20010545A1
Authority
PE
Peru
Prior art keywords
alkyl
composition
treatment
pain
chronic pain
Prior art date
Application number
PE2000000705A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Lee
Alistair Dixon
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20010545A1 publication Critical patent/PE20010545A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
PE2000000705A 1999-07-16 2000-07-14 Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico PE20010545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
PE20010545A1 true PE20010545A1 (es) 2001-06-04

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000705A PE20010545A1 (es) 1999-07-16 2000-07-14 Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico

Country Status (16)

Country Link
EP (1) EP1202726A2 (ko)
JP (1) JP2003504400A (ko)
KR (1) KR20020012315A (ko)
CN (1) CN1373660A (ko)
AR (1) AR024732A1 (ko)
AU (1) AU5786000A (ko)
CA (1) CA2374052A1 (ko)
CO (1) CO5300398A1 (ko)
HU (1) HUP0202623A3 (ko)
IL (1) IL147619A0 (ko)
NZ (1) NZ515567A (ko)
PE (1) PE20010545A1 (ko)
PL (1) PL352684A1 (ko)
TR (1) TR200200082T2 (ko)
WO (1) WO2001005392A2 (ko)
ZA (1) ZA200109907B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
AU2004279721A1 (en) * 2003-10-08 2005-04-21 Teijin Pharma Limited Process for producing aminopyrrolidine derivative and intermediate compound
EP1682495A1 (en) 2003-10-21 2006-07-26 Warner-Lambert Company LLC Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Ｍｅｋ雜環抑制劑及其使用方法
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
MY147628A (en) 2006-07-06 2012-12-31 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CA2692506C (en) 2007-07-05 2015-11-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
WO2009037707A2 (en) * 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
JP5511680B2 (ja) 2007-12-19 2014-06-04 キャンサー・リサーチ・テクノロジー・リミテッド ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用
CA2711699A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2240455B1 (en) 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
CA2923835C (en) * 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA3001879A1 (en) * 2015-10-27 2017-05-04 Acetylon Pharmaceuticals, Inc. Hdac inhibitors for the treatment of diabetic peripheral neuropathy
DK3697405T3 (da) * 2017-10-17 2021-08-23 Atriva Therapeutics Gmbh Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner
CN114008013A (zh) * 2019-06-28 2022-02-01 哥本哈根大学 伴有睡眠障碍的cns病症的治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
ES2274572T3 (es) * 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
WO1999001426A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
JP2002532415A (ja) * 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療

Also Published As

Publication number Publication date
KR20020012315A (ko) 2002-02-15
CN1373660A (zh) 2002-10-09
HUP0202623A3 (en) 2003-03-28
AR024732A1 (es) 2002-10-23
AU5786000A (en) 2001-02-05
EP1202726A2 (en) 2002-05-08
PL352684A1 (en) 2003-09-08
WO2001005392A2 (en) 2001-01-25
JP2003504400A (ja) 2003-02-04
CO5300398A1 (es) 2003-07-31
CA2374052A1 (en) 2001-01-25
NZ515567A (en) 2004-03-26
ZA200109907B (en) 2003-02-28
TR200200082T2 (tr) 2002-04-22
WO2001005392A3 (en) 2001-07-19
IL147619A0 (en) 2002-08-14
HUP0202623A2 (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
PE20010545A1 (es) Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico
PE20010547A1 (es) Uso de una composicion de inhibidores de mek para tratar el dolor cronico
PE20020693A1 (es) Agonistas del receptor alfa activado del proliferador de peroxisomas
AR097445A2 (es) Ésteres oxigenados de ácidos 4-yodo fenilamino benzhidroxámicos
PE20001539A1 (es) Composiciones farmaceuticas con agentes tiromimeticos antiobesidad
FI822943L (fi) Tromboxansyntetas-inhibitorer, processer foer deras framstaellning och farmaceutiska kompositioner innehaollande dessa
MX9603506A (es) Compuestos oxazol aromaticos, heterociclicos y sus usos.
LU88670I2 (fr) Fluvastatine eventuellement sous forme de sel par exemple sel de sodium
TR200001391T2 (tr) Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri.
DE69710204T2 (de) Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
CO5070574A1 (es) Derivado del acido fenoxiacetico y composicion farmaceutica que lo contiene
PE16299A1 (es) Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores
PE20010486A1 (es) Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz
CO5700781A2 (es) Agonistas morfolinicos de la dopamina
ES429234A1 (es) Procedimiento para la preparacion de nuevas amidas de aci- dos n-(1-(omega-fenilalcohil)-piperidil-4)-n-(alfa-piridil)-carboxilicos.
KR950702655A (ko) 신규한 3―치환 파라―아미노페놀과 케라틴섬유 염색에 있어서 이들의 용도(Novel 3―substituted para―aminophenols and use therof in dyeing keratinous fibres)
ES8801175A1 (es) Un procedimiento para preparar derivados de fenil-tioalcanos
ES8102090A1 (es) Procedimiento para la preparacion de acidos w-(2-(n-alcohil inferior-benzamido)-fenil)-alcanoicos
EP0235452A3 (en) Organic compounds and their pharmaceutical use
DE3864660D1 (en) Thiophen-derivate.
TR200202439T2 (tr) Sodyum hidrojen değiştirici tip 1 önleyici (NHE-1)
RS51141B (sr) Supstituisani tiofeni, postupak za njihovu proizvodnju, njihova primena u svojstvu leka, kao i lek koji sadrži ova jedinjenja
ES2165410T3 (es) Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
GB1185334A (en) Thienobenzothiazepines
ZA839552B (en) Optionally active phenoxypropionic acid derivatives

Legal Events

Date Code Title Description
FC Refusal